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a  b  s  t  r  a  c  t
Despite  impressive  gains  over  the  last  15  years  in  reducing  the mortality  associated  with malaria,  it
remains  a public  health  emergency.  New  interventions,  such  as  vaccines,  are  needed  to ensure  that  pre-
vious gains  serve  as a foundation  for future  progress.  Vaccines  have  the  potential  to  prevent  severe  disease
and death  in those  most  vulnerable,  and  to accelerate  elimination  and  eradication  by breaking  the  cycle  of
parasite  transmission.  The  pipeline  is as healthy  as  it has  ever  been,  with  approaches  targeting  different
stages  of  the  parasite  lifecycle  using  an  array  of  technologies.  This  article  reviews  recent  progress  and
reviews  key  considerations  in the  quest  to develop  products  that  are  aligned  with  the  unmet  medical  need.
©  2015  The  Author.  Published  by Elsevier  Ltd.  This  is an  open  access  article  under  the  CC  BY-NC-ND. Introduction
Signiﬁcant progress in reducing malaria morbidity and mor-
ality has been achieved via coordinated scale-up of a range of
nterventions. Between 2000 and 2013, estimated malaria mortal-
ty rates decreased by 47% worldwide and by 54% in Africa. Further,
hile a total of 97 countries remain endemic for malaria, the num-
er is steadily falling with an estimated 34 countries targeting
limination over the next 10–20 years [1]. In view of the fact that
hese impressive gains have been achieved in the absence of an
vailable vaccine, it is critical that vaccine development efforts be
argeted to address the residual, unmet medical need.
The current unmet medical need for vaccines to reduce morbid-
ty and mortality remains most urgent in populations associated
ith the highest burden of disease. This burden remains greatest in
ub-Saharan Africa, where an estimated 90% of all malaria deaths
ccur, and particularly in children aged less than 5 years of age,
ho account for approximately 80% of all deaths. In 2013, an esti-
ated 437,000 African children died before their ﬁfth birthday due
o malaria [1]. Therefore, a vaccine capable of preventing disease
nd death in this population has the potential for signiﬁcant public
ealth impact.
In addition to the development of vaccines to address the imme-
iate unmet medical need associated with malaria morbidity and
ortality, there has been, in recent years, an increased focus on the
evelopment of vaccines to break the cycle of Plasmodium (P.) fal-
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ciparum and Plasmodium vivax parasite transmission to accelerate
future elimination and eradication efforts [2]. Existing interven-
tions have proven to be highly effective in eliminating malaria in
certain settings and reducing malaria transmission to extremely
low levels in many more. Sustaining those gains, however, partic-
ularly once control programs have ended, has proven challenging.
A recent review of 75 resurgence events in 61 countries, occurring
from the 1930s through the 2000s, concluded that almost all resur-
gence events (68/75 = 91%) were attributed at least in part to the
weakening of malaria control measures [3]. In short, the impressive
gains could not be maintained in the absence of labor intensive and
costly programs. New tools, with longer durability, are needed to
interrupt the cycle of malaria (parasite) transmission, prevent par-
asite reintroduction, and accelerate elimination. A leading strategy
is to develop vaccines that interrupt malaria transmission (VIMT)
to provide an ‘immunological bed net’ that prevents parasite trans-
mission [2]. By virtue of the inherent properties of vaccines, this
impact would be achieved in a manner that is independent of
user behavior and the temporal and spatial constraints associated
with other interventions, preventing reintroduction of parasites
into humans and thereby re-establish the human parasite reser-
voir, even in the most challenging environments. Importantly, in
the event of malaria resurgence, vaccines conferring direct clinical
beneﬁt would provide a ‘safety net’ to protect populations ren-
dered vulnerable to severe malaria and death by the lack or loss of
accumulated natural immunity that would accompany elimination
efforts [4].
This article will review the progress toward development of a
malaria vaccine pipeline, sufﬁcient to address global needs associ-
ated with preventing clinical disease (i.e., averting cases, thereby
preventing disease and saving lives) and interrupting the cycle of
transmission (thereby supporting control and elimination). There
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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s a particular emphasis on development progress in the context
f the Malaria Vaccine Technology Roadmap (Roadmap) [5], and a
ocus on key factors that are expected to inﬂuence the environment
n which the malaria vaccine development community is expected
o operate over the coming years.
. Clear community goals: Malaria Vaccine Technology
oadmap
To ensure alignment of vaccine development efforts with the
nmet public health need, the ﬁrst Roadmap was published in
006, following an extensive consultation with scientists and public
ealth experts from non-endemic and malaria-endemic countries,
ndustry, non-governmental organizations, and funding agencies.
his ﬁrst iteration of the Roadmap focused exclusively on the need
o develop vaccines to prevent P. falciparum malaria disease in
oung African children. In 2013, the Roadmap was  updated, again
ased on extensive consultations with key stakeholders [5], to
nclude two strategic goals to be met  by 2030; namely, vaccines that
re highly efﬁcacious in preventing clinical malaria and vaccines
hat prevent transmission to accelerate malaria parasite elimina-
ion. The Roadmap also includes an updated set of priority areas
n research, vaccine development, key capacities, policy, and com-
ercialization, where further funding and activities are likely to be
rucial for success [5].
A landmark goal, established by the ﬁrst Roadmap in 2006, to
evelop and license a ﬁrst-generation malaria vaccine by 2015 that
as a protective efﬁcacy of more than 50% against severe disease
nd death and lasts longer than one year, remained in effect fol-
owing the 2013 revisions. The RTS,S vaccine candidate, developed
y GSK in partnership with the PATH Malaria Vaccine Initiative
ith ﬁnancial support from the Gates Foundation, has the poten-
ial to fulﬁll the landmark goal. Recent progress and next steps
n the development of this vaccine candidate are described in the
ccompanying article (see, ‘RTS,S: a ﬁrst landmark on the Malaria
accine Technology Roadmap’). In June 2014, GSK submitted an
pplication for a scientiﬁc opinion by the Committee for Medicinal
roducts for Human Use (CHMP) on RTS,S through the European
edicine Agency’s (EMA) Article 58 procedure. The EMA  is eval-
ating data on the quality, safety, and efﬁcacy of the RTS,S/AS01
accine candidate. On Thursday, July 23, 2015, CHMP adopted a
ositive opinion. This is not licensure, but will be helpful to African
egulatory authorities as they receive submissions, knowing that a
tringent regulatory authority has provided a positive assessment
f quality and risk/beneﬁt. The WHO  will issue policy recommen-
ations regarding the RTS,S malaria vaccine candidate as early as
he fourth quarter of 2015. The EMA  assessment does not include
spects such as feasibility of implementation, cost-effectiveness,
nd the role of RTS,S in the context of available malaria control
easures, all of which will be important parts of the WHO  policy
ecommendation process.
The relatively modest vaccine efﬁcacy (VE) criteria for the 2006
andmark Roadmap goal was justiﬁed based on the potential for
igh public health impact. Indeed, several examples of how VE,
he traditional barometer of vaccine performance, often imper-
ectly predicts the public health impact of a vaccine on disease
urden, including for the most advanced malaria vaccine candi-
ate (RTS,S/AS01), have been reported [7]. It has been proposed that
PDI (Vaccine Preventable Disease Incidence), which assesses the
mount of disease prevented when considering both VE and base-
ine disease incidence, is a superior measure of public health impact
gainst severe clinical disease/syndromes. This measure provides direct assessment of the preventable incidence of the most rel-
vant public health outcome for policymakers. Over the coming
ears, these measurements could be inﬂuenced, toward a potential
or greater public health impact, in view of the emerging resistance2015) 7538–7543 7539
to malaria interventions that have been temporally associated with
the gains of the last 10–15 years. Speciﬁcally, the spread of resis-
tance across Africa to insecticides in Anopheline mosquitoes, and
the ever closer threat of resistance to leading Artemisinin Combina-
tion Therapies (ACT) reaching the African continent [8–11], without
the near term prospect of alternative molecules, may cause the
value of other available interventions, imperfect as they may  be,
to be viewed in a different light.
While the Roadmap goals provide high-level targets for malaria
vaccine development efforts, additional speciﬁcity is needed to
describe the preferred characteristics of vaccines to ensure that
they are ‘ﬁt-for-purpose’ to achieve the desired impact. In recogni-
tion of this need, a series of preferred product characteristics (PPCs)
were recently published by the WHO  [12]. The PPCs describe pre-
ferences for parameters of vaccines, in particular their indications,
target groups, and possible immunization strategies, as well as the
clinical data desired related to safety and efﬁcacy. PPCs are meant
to provide early guidance for the development of new products or
the improvement of existing ones. Each PPC addresses early-stage
vaccine R&D generally at least 5–10 years from the vaccine’s avail-
ability, and will be reviewed and updated if necessary, at least every
5 years. PPCs are not static exit criteria, but are structured in such a
way so as to drive innovation towards meeting public health needs
[12].
A critical gap in the current proﬁle of elimination vaccines
is the target protective efﬁcacy and coverage levels required to
confer sufﬁcient community immunity to prevent reintroduction,
under a given transmission setting. This will need to be esti-
mated, over the coming years, to support investment decisions
associated with advanced clinical development where accelerat-
ing elimination and eradication is the primary investment driver.
Initial mathematical modeling studies have suggested that very
high levels of efﬁcacy (and coverage) will be needed, particularly
in high transmission settings [13,14]; however, new population-
based preclinical models have suggested that elimination could
be achieved by transmission-interrupting interventions exhibit-
ing relatively modest efﬁcacy at low transmission settings [15].
Therefore, a cautious approach is warranted in using mathematical
models to inform product development decisions with integration
of biological data and realistic assumptions critical to their optimal
use.
3. Financing the malaria vaccine development pipeline
The absence of a signiﬁcant developed world market for malaria
vaccines has led to a heavy reliance on public and philanthropic
funding to support development efforts. From 2007 to 2011, pub-
lic funders contributed 44% ($327 million) of malaria vaccine R&D
funding, whilst philanthropic organizations accounted for 36%
($267 million) and industry for 20% ($148 million) [16]. While dif-
ferent funding agencies generally favor one or other of the Roadmap
goals, they are generally aligned with one of the two goals associ-
ated with P. falciparum.  However, there continues to be a chronic
lack of support for the development of P. vivax vaccines to prevent
clinical disease and to prevent transmission. A major contributor
to this deﬁciency is continued prioritization of P. falciparum,  over
P. vivax, for the limited available resources. A major risk of this
approach is that vaccines to interrupt P. vivax transmission, which
is recognized as being a signiﬁcantly greater challenge than for P.
falciparum, will not be available in a timely manner to support the
eradication agenda [17].An opportunity associated with this challenging environment,
particularly in the context of clear community goals and preferred
product characteristics (also discussed above), is the application
of a portfolio-based investment strategy to ensure optimal use
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f limited resources. This investment strategy is most appro-
riate in the pre-proof-of-concept development phase to enable
aximal ﬂexibility in resource allocation. This is achieved by
acilitating ‘real-time’ responses to new data to increase or
ecrease investment in speciﬁc projects, in the context of the
erformance of a broader portfolio of projects. Retaining an
bility to reallocate resources across a portfolio of projects dur-
ng early-stage development supports the focus on achieving
he product development goal as opposed to a speciﬁc vaccine
pproach that may  or may  not speciﬁcally achieve the desired
utcome.
However, once proof-of-concept has been successfully achieved
n the target population, and the vaccine is considered ‘ﬁt-for-
urpose’ based on alignment with preferred product characteris-
ics, a strong case can be made for an alternative funding strategy;
amely, a product-speciﬁc investment. The highly deﬁned and
ore substantial ﬁnancial requirements associated with late-stage
evelopment are preferably isolated from pre-proof-of-concept
nvestments, in large part to protect the relatively modest budget
ssociated with them.
. Commercial considerations for different classes of
accines under development
Malaria vaccines are being developed to beneﬁt individuals liv-
ng in some of the poorest communities on earth, and therefore
onsidered to be of limited commercial value. The different classes
f vaccine under development, whether to prevent clinical malaria
n at risk populations (Roadmap Goal 1) or to reduce transmis-
ion to accelerate elimination (Roadmap Goal 2), are associated
ith deﬁned ‘use case’ scenarios that make the two vaccine classes
uite distinct. These distinctions, which are summarized in Table 1,
ill need to be considered early in development and are likely to
e of key strategic interest to vaccine developers/manufacturers.
n addition to the obvious differential in ‘beneﬁt’ (i.e., individ-
al/disease versus community/elimination), the target population
nd associated implementation strategies are expected to be dis-
inct. Vaccines intended to prevent clinical disease are most likely to
e delivered via established immunization program mechanisms,
hich are expected to ensure coverage for those enduring the
reatest burden of disease; this, in turn, is likely to provide a consis-
ent and predictable demand that is favorable to the manufacture.
onversely, vaccines being deployed for elimination will need to
arget all individuals at risk of becoming infected and/or transmit-
ing the parasite, a level of coverage only likely to be achievable
ia mass campaigns; in turn, this is likely to lead to an uncertain
emand dependent on the timing and size of elimination cam-
aigns.
The product lifecycle for each type of vaccine is simi-
arly expected to be distinct, with vaccines targeting standard
mmunization programs associated with a more favorable busi-
ess model, which can be likened to a multi-decade annuity
ith favorable capital amortization and high barrier to biosim-
lar entry. Vaccines for elimination can be likened more to
atented drugs, with rapid market growth and a demand cliff
nce eradication has been achieved; this is likely to lead
o the developer/manufacturer retaining signiﬁcant stranded
ssets.
Additional commercial considerations include deﬁnition of
etrics to assess public health impact and return on investment
or elimination vaccines. For vaccines preventing clinical disease,
ost-effectiveness can be determined using well-deﬁned metrics.
owever, the ‘value for money’ of elimination products that, par-
icularly late in elimination campaigns, will be associated with
inimal reduction in clinical cases, will need to be determined.2015) 7538–7543
5. Regulatory considerations for next-generation vaccines
Identiﬁcation of a regulatory acceptable correlate of pro-
tection for RTS,S will signiﬁcantly accelerate development of
next-generation vaccines targeting the circumsporozoite protein
(CSP), in large part by avoiding the need for costly Phase 3 efﬁcacy
trials. In the absence of a regulatory acceptable correlate of pro-
tection, vaccines intended to prevent clinical malaria by targeting
at-risk populations (Roadmap Goal 1) are associated with a tra-
ditional development pathway that is likely to be similar to the
one followed by RTS,S [18]. In view of the absence of an approved
malaria vaccine, RTS,S was evaluated in a series of trials in which the
comparator (control) vaccine was not targeting malaria. However,
in the event that RTS,S is recommended for use, novel vaccines tar-
geting a similar indication (i.e., prevention of P. falciparum malaria
disease in young African children) will require consideration of the
inclusion of RTS,S as a comparator vaccine, which could present
technical and ﬁnancial challenges due to the size of trial needed
to effectively demonstrate non-inferiority, or superiority, to RTS,S.
Alternatively, there are ethical issues associated with vaccine tri-
als assessing vaccine efﬁcacy and/or effectiveness, where a placebo
is being considered in the study design despite the existence of
an efﬁcacious vaccine. This challenge is not unique to malaria,
having been faced by other vaccine development efforts where
ﬁrst-generation products failed to fully address the unmet medi-
cal need associated with a disease, particularly in resource-limited
settings. Examples include development of novel rotavirus vaccines
in India and novel pneumococcal vaccines in Bangladesh.
A 2013 expert consultation led by the WHO  identiﬁed ﬁve sit-
uations in which placebos may  be ethically acceptable even in the
presence of an efﬁcacious vaccine [19]. One of the situations per-
tains to resource constraints associated with access to the existing
vaccine that could be overcome by the next-generation product.
The other four situations relate to scientiﬁc constraints, one or more
of which may  be relevant; however, this would need to be consid-
ered in the context of the proﬁle of the next-generation vaccines
under consideration.
In recent years, there has been an increased focus on devel-
opment of vaccines that interrupt malaria (parasite) transmission
(VIMT) to support malaria elimination [5]. The two primary vac-
cine development strategies are to induce pre-erythrocytic (PE)
immunity that prevents infection of humans or to induce sex-
ual, sporogonic, or mosquito-stage (SSM) immunity to prevent
transmission to mosquitoes [20]. While the focus of these vac-
cines is to prevent infections (as opposed to clinical disease), it is
important to note that infection endpoints have historically not
been sufﬁcient to support vaccine licensure. Furthermore, SSM-
VIMT would not confer immediate, direct clinical beneﬁt to the
recipient, unless paired with an intervention that provides such a
beneﬁt. In the absence of such pairing, cluster-randomized trials
have been considered the default pathway to regulatory approval
and expert consultations have recently presided over potential
study designs for pivotal Phase 3 cluster-randomized trials for
an SSM-VIMT [21]. In addition, exploration of innovative regula-
tory pathways for next-generation malaria vaccines that interrupt
transmission to encourage the development of this important class
of interventions—while at the same time safeguarding the health
and well-being of the population that SSM-VIMT are intended
to beneﬁt—is urgently needed. One consideration under active
discussion is the potential eligibility of SSM-VIMT for an Accel-
erated Approval (AA) method of licensure by the US Food and
Drug Administration, based on a proposed surrogate endpoint with
conﬁrmatory trials performed post-licensure [22]. Resolving this
important dilemma will require vaccine developers and other key
stakeholders to work closely with regulatory authorities, including
those in endemic counties, and with the WHO. An important step
A.J. Birkett / Vaccine 33 (2015) 7538–7543 7541
Table  1
Characteristics of malaria vaccines to prevent clinical disease versus acceleration of elimination.
Characteristics Vaccine to prevent disease (Roadmap Goal 1) Vaccine to accelerate elimination (Roadmap Goal 2)
Beneﬁt Focus on preventing disease in individuals; indirect
herd beneﬁt as a post-licensure upside
Focus on prevention of population-based parasite
transmission ± individual beneﬁt
Target population Focus on infant/children in sub-Saharan Africa Entire population at risk and transmitting parasite—high coverage required
Use  EPI schedule; indeﬁnite in birth cohorts Campaigns ± routine use. Given with ARC. Limited duration of use
Regulatory pathway Clearly deﬁned based on direct clinical beneﬁt Regulatory pathway for SSM-VIMT to be deﬁned. Policy recommendation
critical
Manufacturing Calculated on constant use in birth cohort Time-limited, demand forecasts need to consider timing of campaigns
COGs Cost effectiveness determined by well-deﬁned metrics Agreed upon metrics needed to determine value for money of elimination
products
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with favorable capital amortization and high barrier
biosimilar entry
orward in this regard was achieved at the inaugural convening of
he WHO  Product Development for Vaccines Advisory Committee
eeting held in Geneva, September 8–10, 2014, where a speciﬁc
ecommendation was that identiﬁcation of a feasible regulatory
athway for TBVs be a priority area of work for the WHO  [23].
. Controlled human malaria infection (CHMI) models:
ccelerating and de-risking future vaccine development
fforts
Controlled human malaria infection (CHMI) models have served
s important stage gates in the early clinical development of
alaria vaccine candidates and are likely to continue to serve a
imilar role going forward [24]. The use of CHMI models has facili-
ated rapid and cost-effective assessment of vaccine candidates for
heir efﬁcacy against infection, informing the decision to advance
o ﬁeld efﬁcacy studies. The most widely used malaria CHMI model
mployed to date involves experimental infection of volunteers
ia the bites of infectious mosquitoes [25,26]. While the endpoint
or this model is infection, as determined by asexual blood-stage
arasitemia measured by microscopy or polymerase chain reac-
ion (PCR), parasitemia has proven to be a valuable proxy for the
evelopment of vaccines, such as RTS,S, with a target indication of
revention of clinical malaria [27].
In recent years, two  groups have reported successful sporozoite
hallenge studies in human volunteers using P. vivax strains derived
rom human donors [28,29]. Further, the development of infec-
ious, puriﬁed, and vialed sporozoites now offers the potential to
erform CHMI studies in the absence of insectary requirements,
ith studies ongoing to optimize dose and route to ensure reli-
ble infectivity in non-endemic [30,31] and endemic populations
32,33]. In view of the unnatural challenge route for puriﬁed vialed
porozoites (direct intravenous inoculation), its value as a stage
ate to inform advancement to efﬁcacy studies in endemic regions
as yet to be proven. Speciﬁcally, concerns have been raised that
irect venous inoculation (DVI) of vialed sporozoites could bypass
mmune mediated protection in the skin, which is known to inter-
ere with sporozoite motility [34]. It will therefore be important
o assess the DVI model, with mosquito challenge serving as the
old standard, for testing pre-erythrocytic vaccines with presumed
ntibody-mediated mechanisms of protection.
Signiﬁcant innovation in the use of CHMI models has occurred
ver the past several years, which has the potential to further
nhance the tools available to accelerate vaccine development
fforts and reduce risk of failure during operationally complex and
xpensive ﬁeld studies. This need is most urgent in the assess-
ent of vaccines targeting asexual blood-stage and sexual-stagentigens, where there has historically been a strong reliance on
eadouts from functional assays that have not been conclusively
hown to correlate with clinical outcomes. Such CHMI models will
lso strengthen the ability to test existing assumptions and newMore similar to patented drug with rapid market growth and then demand
cliff; large upfront capital investment with subsequent stranded assets
hypothesizes associated with functional assays, as well as to inves-
tigate more rigorously immune correlates of protection. Sexual
blood-stage challenge models, ﬁrst developed in the 1990s, have
emerged as a potential tool to better inform the development of
these two  classes of vaccine [35]. The blood-stage model involves
direct intravenous infection with low numbers of asexual blood-
stage parasites, which replicate in vivo in a reproducible manner
[35–37]. Bypassing the liver stage results in a more consistent
blood-stage infection, which can be effectively monitored (using
PCR) over a longer period of time. This ability to induce a consistent,
low-grade asexual blood-stage parasitemia offers the potential to
support the assessment of the impact of vaccine-induced immu-
nity, and possibly passively-transferred immunity, on the parasite
multiplication rate (PMR) of asexual-stage parasites [36,37].
The ﬁrst test of concept to assess a vaccine candidate using
the blood-stage CHMI model was  with AMA1-C1/Alhydrogel + CPG
7909; however, it failed to induce immune responses that reduced
the overall mean PMR  in the vaccine group in comparison to the
controls [38]. More recently, another AMA1 vaccine candidate vac-
cine candidate (FMP2.1/AS02B), derived from 3D7-strain parasites,
was assessed in the same model. When formulated with AS02
adjuvant, this vaccine candidate was shown to induce a low level
of vaccine efﬁcacy against clinical malaria in Malian children (VE
17.4%—hazard ratio for the primary end point, 0.83; 95% conﬁ-
dence interval [CI], 0.63–1.09; P = 0.18). Efﬁcacy against clinical
malaria caused by parasites with AMA1 corresponding to that of
the vaccine strain was  64.3% (hazard ratio, 0.36; 95% CI, 0.08–0.86;
P = 0.03) [39]. To determine whether these ﬁndings could be ‘back
validated’ to the blood-stage CHMI model, 15 healthy, malaria-
naïve volunteers were immunized with 3 doses of FMP2.1 in AS01B
using the same schedule as used in the ﬁeld [40]. Despite being
immunogenic, eliciting functional IgG-mediated growth inhibition
assay (GIA) in vitro against 3D7 clone parasites, there was  no delay
to diagnosis seen in the vaccinees compared with controls. The
mean PMR  in vaccinees, modeled from the quantitative PCR (qPCR)
data by protocol pre-speciﬁed methodology, was 10.32 (95% CI,
8.97–11.67) and in controls was  10.31 (95% CI, 9.00–11.62), demon-
strating no signiﬁcant difference [40]. These observations suggest
that the blood-stage CHMI model could serve as an important
stage-gate in the early clinical assessment of asexual blood-stage
vaccines by determining whether induced immunity has a bio-
logical effect on parasite replication in vivo, and supporting the
identiﬁcation of immune correlates. The development of banks
of parasites that are antigenically distinct, at key vaccine target
alleles, offers the potential for CHMI studies to estimate the capac-
ity of novel immune interventions to function against a diverse
parasite repertoire in advance of advancing to endemic ﬁeld stud-
ies.
A second potential use of the blood-stage CHMI model is in the
evaluation of human-to-mosquito transmission for transmission-
blocking vaccines. For P. vivax, this may  be achievable following
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sexual blood-stage challenge, as evidenced from the recent
bservations from McCarthy and colleagues, where gametocytes
here identiﬁed in the blood as early as two days after the onset
f PCR-conﬁrmed parasitemia and more than two days before
he onset of symptoms or slide positivity [41]. While infectivity
o mosquitoes of these sexual stages was not conﬁrmed in this
tudy, the authors highlighted the consistency of their ﬁndings
ith previous reports documenting the infectiousness of patients
ith early P. vivax infection. Records of volunteers with induced P.
ivax infection for malariotherapy for syphilis showed that 39.3%
f mosquitoes that fed on patients with similar sub-microscopic
ametocytemia became infected [42]. For P. falciparum,  where
ametocytes are produced later following human infection, it is
ikely that manipulation of the model, using anti-malaria drugs
o differentially suppress asexual-stage parasites but not sexual-
tage parasites, will be needed. In addition to testing immune
nterventions for their capacity to block human-to-mosquito
ransmission following direct skin feeding, this model has the
otential to enable a better understanding of the association of the
tandard membrane feeding assay and direct membrane feeding
ssay with direct skin feeding [22,43].
. Malaria vaccine portfolio
The global malaria vaccine portfolio is actively monitored via
 WHO-led initiative known as the ‘Rainbow Tables’, which was
ost recently reviewed in a 2012 manuscript [44]. Projects in the
atabase are organized based on the parasite target (i.e., P. falcip-
rum or P. vivax), the stage of the parasite lifecycle being targeted
i.e., pre-erythrocytic, asexual blood-stage, sexual stage, or mul-
istage), and the current development stage (i.e., pre-clinical or
linical). According to the most recent online version of the Rain-
ow Tables, updated in January 2015, there are a total of 33 active
linical-stage vaccine projects. The overwhelming majority of these
re targeting P. falciparum (32/33), with only one targeting P. vivax.
he dominant lifecycle-stages being target are pre-erythrocytic and
sexual blood-stage (15/33 each), with sexual stage (2/33) and mul-
istage (1/33) continuing to be the minorities.
Subunit pre-erythrocytic vaccine approaches are generally
ominated by three antigens: CSP, TRAP, and CelTOS, with four
f the CSP projects aiming to build directly on the RTS,S/AS01
accine candidate that recently completed Phase 3 testing. Irra-
iated sporozoites (PfSPZ), delivered intravenously, have been
hown to protect six subjects receiving ﬁve doses and three
f nine subjects receiving four doses of 1.35 × 105 (Note: only
ve of six non-vaccinated controls were infected following con-
rolled human malaria infection; P = 0.015 in the ﬁve-dose group
nd P = 0.028 overall, both versus controls) [45]. Initial clinical
esting of a genetically attenuated sporozoite vaccine approach,
elivered via mosquito bites, led to breakthrough infection associ-
ted with incomplete attenuation [46]; however, next-generation
arasites are expected to be tested over the coming years
47,48].
The portfolio of clinical-stage asexual blood-stage vaccine
pproaches is the most diverse with a total of nine antigens
nder investigation (AMA1, EBA175, GLURP, MSP1, MSP3, Pf11.1,
FF0165c, RH5, and SERA5). Over the coming years, one or more
AR2CSA-based vaccines approaches are expected to transition to
nitial clinical-stage testing, with the long-term goal of preventing
regnancy-associated malaria [49].
The only two sexual-stage clinical projects target a single anti-
en (Pfs25), highlighting the need for new target antigens to
ransition to clinical testing. Pfs230 is expected to be only the sec-
nd sexual-stage antigen to progress to human clinical testing over
he next one to two years.2015) 7538–7543
8. Concluding remarks
Since the ﬁrst iteration of the Malaria Vaccine Technology
Roadmap was published almost 10 years ago, signiﬁcant progress
has been made toward achieving the 2015 landmark goal of a ﬁrst-
generation P. falciparum vaccine to protect those at greatest risk
from severe disease and death: young African children. As a result of
the 2013 revision to the Roadmap, and availability of PPCs and TPPs,
the community now has greater clarity on the required attributes
of next-generation vaccines, including those that will be essential
to ensure effective implementation.
While the pipeline is impressive, with diverse approaches tar-
geting different parasite development stages, it would beneﬁt from
a broader list of promising target antigens on which to draw. There
has been a movement in this direction in recent years, with tar-
gets such as CelTOS, RH5, and VAR2CSA at or nearing initial clinical
assessment, but more are needed [49–51]. Novel approaches to
validating vaccine target antigens, such as via passive transfer of
monoclonal antibodies, followed by CHMI, are advancing with the
potential to accelerate development efforts; however, they remain
as yet unproven.
A signiﬁcant opportunity is associated with understanding of
the protective mechanism of the remarkable ﬁnding that vol-
unteers immunized under chloroquine chemoprophylaxis with
P. falciparum sporozoites (CPS) exhibit durable protection from
homologous challenge following bites from just 45 infected
mosquitoes [52,53]. Such knowledge has the potential to be trans-
lated into novel vaccine development strategies, founded on strong
biological rationale, and thereby further diversify and strengthen
the global malaria vaccine development portfolio.
Of signiﬁcant importance is the recent progress toward the
expanded use of CHMI models to include the assessment of asexual
blood-stage and transmission-blocking vaccines to support stage-
gate decisions for many vaccines in the current pipeline. If used
effectively, these models have the potential to increase the prob-
ability of success for vaccine approaches that advance to endemic
ﬁeld-testing and thereby ensure optimal use of precious resources.
In view of the fact that developing vaccines inducing durable pro-
tection is likely to prove more challenging than conferring a high
level of efﬁcacy over a short period, the manner in which CHMI
models are used and interpreted will be critical. Therefore, we
will need to not only ‘raise the bar’ with respect to target efﬁcacy,
but also with respect to durability of protection by placing greater
emphasis on challenge results obtained at more distant time points
following immunization.
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